The smoke had barely lifted from the New Year fireworks when Novo Holdings announced its first acquisition of 2022 – US company Medical Knowledge Group (MKG).
The firm, which is based in New York and was founded in 2004, has developed a new platform to launch new drugs, and Managing Partner at Novo Holdings Christoffer Søderberg says that this is very interesting in a time when commercializing new drugs is becoming more and more complex.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.